The overall goal of the Population Sciences and Health Disparities Program is to conduct research to delineate and mitigate factors that affect the occurrence (or non-occurrence) of cancer in human populations and their differential manifestations in health status to ultimately reduce avoidable cancer incidence, morbidity, mortality, and to improve the quality of life for those affected by cancer (i.e. survivors and their families). Members from a variety of disciplines contribute their expertise to elucidating variabilities in cancer risk among human populations due to (A) behavioral, socio-demographic, and cultural factors;and/or (B) due to health systems factors. The Program's major research accomplishments include (1) Delineating tobacco as the key to reducing cancer through policy and practice interventions;(2) Delineating new cancer disparities across racial/ethnic and socio-demographic populations and across multiple tumor types;(3) Enhancing cancer detection, treatment, and survival through analyses of large datasets;and (4) Systematically delineating and mitigating hepatitis B viral infections as a pathway to reduce liver cancer disparities. The program has six intervention research grants focused on mitigating cancer health disparities among African Americans, American Indians, Asian Americans, and Latinos. Our P01program project, "Liver Cancer Control Interventions for Asian Americans" is the only community-based program project. We are funded as the "National Center for Reducing Asian American Cancer Health Disparities". The foundation of our research efforts are our multidisciplinary approach, our collaboration with registry epidemiologists, and our use of data from longitudinal cohort studies. The program has 24 members with affiliations to 13 different departments at UC Davis, LLNL, Kaiser Permanante, and CADHS. It has 14 NCl-funded projects for $3.5 million ADC (total peer-reviewed funding, $5.6 million ADC). The group has 322 publications for the last funding period;23% are inter-programmatic and 13% are intra-programmatic.
The Population Sciences and Health Disparities Program aims to conduct research and disseminate its findings that provide empirically-based insights that can lead to earlier cancer detection, improve the quality of life and care for cancer survivors and their families, enroll more minority patients into cancer clinical trials, and foster transdisciplinary team science approaches to reducing the cancer burden.
|Semrad, Thomas; Barzi, Afsaneh; Lenz, Heinz-Josef et al. (2015) Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol 20:518-24|
|Brostoff, Terza; Dela Cruz Jr, Florante N; Church, Molly E et al. (2014) The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol 88:12816-24|
|Kirschbaum, Mark H; Foon, Kenneth A; Frankel, Paul et al. (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55:2301-4|
|Mayadev, Jyoti; Qi, Lihong; Lentz, Susan et al. (2014) Implant time and process efficiency for CT-guided high-dose-rate brachytherapy for cervical cancer. Brachytherapy 13:233-9|
|Daly, Megan E; Beckett, Laurel A; Chen, Allen M (2014) Does early posttreatment surveillance imaging affect subsequent management following stereotactic body radiation therapy for early-stage non-small cell lung cancer? Pract Radiat Oncol 4:240-6|
|Li, Tianhong; Maus, Martin K H; Desai, Sonal J et al. (2014) Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 9:18-25|
|Campbell, Mel; Kim, Kevin Y; Chang, Pei-Ching et al. (2014) A lytic viral long noncoding RNA modulates the function of a latent protein. J Virol 88:1843-8|
|Li, Tianhong; Kung, Hsing-Jien; Mack, Philip C et al. (2013) Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 31:1039-49|
|Semrad, Thomas J; Eddings, Courtney; Dutia, Mrinal P et al. (2013) Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs 24:636-40|
|Maus, Martin K H; Mack, Philip C; Astrow, Stephanie H et al. (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-6|
Showing the most recent 10 out of 84 publications